Business
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies for FSAD SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG), of the Phase 2b study efficacy results of topical Sildenafil Cream 3.6% (Sildenafil Cream), which is being developed for the treatment of female sexual arousal disorder (FSAD). The Phase 2b clinical study was designed as an exploratory, multi-center, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with FSAD. Topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm. “Arousal disorder represents a significant unmet need, impacting approximately 20% of women in the U.S.¹,” said Dr. Annie Thurman, MD, FACOG, Medical Director at Daré Bioscience. “Publication of this efficacy manuscript in an important peer-reviewed medical journal validates the importance of these findings for the field, shedding light for the first time on which women with FSAD and symptoms can be expected to benefit most from the increased genital blood flow that Sildenafil Cream mechanistically provides, and further underscores the potential of Sildenafil Cream to address the unmet need and improve outcomes for women with FSAD.” “We are so pleased that this manuscript has been accepted in the official publication of the American College of Obstetricians and Gynecologists,” added Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “It truly underscores the importance of these groundbreaking data and can hopefully continue to advance the field with the insights these data provide into this patient po...